BRPI0911385B8 - polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica - Google Patents

polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica

Info

Publication number
BRPI0911385B8
BRPI0911385B8 BRPI0911385A BRPI0911385A BRPI0911385B8 BR PI0911385 B8 BRPI0911385 B8 BR PI0911385B8 BR PI0911385 A BRPI0911385 A BR PI0911385A BR PI0911385 A BRPI0911385 A BR PI0911385A BR PI0911385 B8 BRPI0911385 B8 BR PI0911385B8
Authority
BR
Brazil
Prior art keywords
polypeptide
multimer
pharmaceutical composition
fusion polypeptide
isolated
Prior art date
Application number
BRPI0911385A
Other languages
English (en)
Portuguese (pt)
Inventor
Eva Hamburger Agnes
John Belouski Edward
Sun Jeonghoon
Xu Jing
Leo Michaels Mark
Marie Ellison Murielle
Ira Hecht Randy
Li Yue-Sheng
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40984291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911385(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to BR122020010972-6A priority Critical patent/BR122020010972B1/pt
Publication of BRPI0911385A2 publication Critical patent/BRPI0911385A2/pt
Publication of BRPI0911385B1 publication Critical patent/BRPI0911385B1/pt
Publication of BRPI0911385B8 publication Critical patent/BRPI0911385B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
BRPI0911385A 2008-06-04 2009-06-03 polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica BRPI0911385B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020010972-6A BR122020010972B1 (pt) 2008-06-04 2009-06-03 polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5891908P 2008-06-04 2008-06-04
US5886108P 2008-06-04 2008-06-04
US61/058,919 2008-06-04
US61/058,861 2008-06-04
US16436409P 2009-03-27 2009-03-27
US61/164,364 2009-03-27
US17573609P 2009-05-05 2009-05-05
US61/175,736 2009-05-05
PCT/US2009/046113 WO2009149171A2 (fr) 2008-06-04 2009-06-03 Mutants fgf21 et leurs utilisations

Publications (3)

Publication Number Publication Date
BRPI0911385A2 BRPI0911385A2 (pt) 2019-03-26
BRPI0911385B1 BRPI0911385B1 (pt) 2021-04-13
BRPI0911385B8 true BRPI0911385B8 (pt) 2021-09-14

Family

ID=40984291

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0911385A BRPI0911385B8 (pt) 2008-06-04 2009-06-03 polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
BR122020010972-6A BR122020010972B1 (pt) 2008-06-04 2009-06-03 polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020010972-6A BR122020010972B1 (pt) 2008-06-04 2009-06-03 polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero

Country Status (23)

Country Link
US (10) US8034770B2 (fr)
EP (1) EP2296690B1 (fr)
JP (5) JP2011523561A (fr)
KR (2) KR101787300B1 (fr)
CN (1) CN102143758B (fr)
AR (1) AR072009A1 (fr)
AU (1) AU2009256232B2 (fr)
BR (2) BRPI0911385B8 (fr)
CA (1) CA2726589C (fr)
CL (1) CL2010001346A1 (fr)
CO (1) CO6341566A2 (fr)
CR (1) CR11851A (fr)
EA (3) EA034847B1 (fr)
IL (1) IL209395A (fr)
JO (1) JOP20190083B1 (fr)
MA (1) MA33142B1 (fr)
MX (2) MX346396B (fr)
MY (1) MY152721A (fr)
NZ (1) NZ590050A (fr)
PE (1) PE20100253A1 (fr)
SG (1) SG193860A1 (fr)
TW (2) TWI403519B (fr)
WO (1) WO2009149171A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
NZ592009A (en) * 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (fr) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants de facteurde croissance 21 du fibroblaste
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) * 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
JP2012530493A (ja) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
WO2011006072A2 (fr) * 2009-07-10 2011-01-13 Northwestern University Rôle cardioprotecteur de facteurs sécrétoires de cellules hépatiques et d’hépatocytes dans l’ischémie myocardique
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011130417A2 (fr) 2010-04-15 2011-10-20 Amgen Inc. Protéines de liaison au récepteur de fgf humain et à β-klotho
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2796459C (fr) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Procedes de traitement de troubles metaboliques utilisant le fgf-1
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
MX2013002208A (es) 2010-08-23 2013-05-30 Amgen Inc Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
SG190082A1 (en) 2010-11-05 2013-06-28 Covx Technologies Ireland Ltd Anti-diabetic compounds
CN102464712A (zh) * 2010-11-11 2012-05-23 重庆富进生物医药有限公司 缺失型人成纤维细胞生长因子21变异体及其偶联物
WO2012138776A1 (fr) 2011-04-05 2012-10-11 Amgen Inc. Benzodioxépine et composés de benzodioxine qui interagissent avec la protéine régulatrice de la glucokinase pour le traitement du diabète
US8754044B2 (en) 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2013033452A2 (fr) 2011-08-31 2013-03-07 Amgen Inc. Procédé de traitement ou d'amélioration du diabète type i employant fgf21
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
WO2013123444A1 (fr) 2012-02-17 2013-08-22 Amgen Inc. Composés de sulfonyle qui interagissent avec la protéine régulatrice de la glucokinase
WO2013131091A1 (fr) 2012-03-02 2013-09-06 New York University Protéines chimères fgf21 ayant une affinité de liaison augmentée pour le bêta-klotho dans le traitement du diabète de type ii, de l'obésité et des troubles métaboliques apparentés
WO2013173382A1 (fr) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophène sulfonamides et autres composés qui interagissent avec une protéine régulatrice de la glucokinase
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AR092076A1 (es) * 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
EP3798228A1 (fr) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions et procédés pour le traitement de troubles métaboliques et de maladies
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2014130659A1 (fr) 2013-02-22 2014-08-28 New York University Protéines chimères du facteur de croissance des fibroblastes 23 et méthodes d'utilisation
WO2014149699A1 (fr) 2013-03-15 2014-09-25 Eli Lilly And Company Protéine bifonctionnelle
CN103191415A (zh) * 2013-04-03 2013-07-10 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备治疗高血压的药物中的应用
EP3057605A1 (fr) 2013-10-18 2016-08-24 Novartis AG Méthodes de traitement du diabete et de troubles associés
WO2015061361A1 (fr) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Facteur de croissance de fibroblaste 1 (fgf) muté et méthodes d'utilisation
WO2015061331A1 (fr) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Peptides de facteur de croissance des fibroblastes (fgf) 2/fgf1 chimériques et procédés d'utilisation
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
WO2015138278A1 (fr) 2014-03-11 2015-09-17 Novartis Ag Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline
MX373805B (es) 2014-03-25 2020-03-24 Regeneron Pharma Agonistas de receptor fgf21 y usos del mismo.
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (fr) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
WO2016065052A1 (fr) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués insuline vitamine d
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
RS59154B1 (sr) 2014-12-23 2019-10-31 Novo Nordisk As Fgf21 derivati i njihova upotreba
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017116207A1 (fr) * 2015-12-31 2017-07-06 한미약품 주식회사 Analogue de fgf21, conjugué de fgf21 et leur utilisation
US20190142963A1 (en) * 2016-04-15 2019-05-16 Richard D. DiMarchi Fgf21 c-terminal peptide optimization
SG11201900459RA (en) 2016-08-01 2019-02-27 Univ Beijing Mg53 mutants, methods of making the same, and uses thereof
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
HUE071618T2 (hu) * 2016-11-10 2025-09-28 Yuhan Corp Fúziós fehérjéket tartalmazó gyógyszerkészítmény hepatitisz, májfibrózis és májzsugor megelõzésére vagy kezelésére
CA3047862A1 (fr) 2016-12-22 2018-06-28 Sanofi Combinaisons d'agonistes du compose fgf21/agoniste du glp-1r ayant un rapport d'activite optimise
WO2018166461A1 (fr) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
CA3069143A1 (fr) * 2017-07-06 2019-01-10 Yale University Compositions et methodes de traitement ou de prevention de maladies liees au fgf endocrinien
CN111050786A (zh) 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
CN115109166B (zh) * 2017-11-24 2025-07-18 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109929806B (zh) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
WO2019123427A1 (fr) 2017-12-22 2019-06-27 Novartis Ag Procédés de traitement de troubles métaboliques avec des variants de fgf21
CN116098989B (zh) 2018-02-08 2026-03-20 广东东阳光药业股份有限公司 Fgf21变体、融合蛋白及其应用
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
IL283452B2 (en) 2018-11-26 2026-04-01 Univ Barcelona Autonoma FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY
AU2020230668B2 (en) 2019-03-05 2025-05-29 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US20220016211A1 (en) 2020-01-08 2022-01-20 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
JP7392491B2 (ja) * 2020-01-21 2023-12-06 トヨタ自動車株式会社 電源システム
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022032187A1 (fr) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose
EP4215607A4 (fr) * 2020-09-18 2024-11-06 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Protéine de fusion ptpsigma-fc et composition pharmaceutique la comprenant
WO2022115597A1 (fr) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Méthodes de traitement de maladies du foie
JP2024531980A (ja) 2021-09-08 2024-09-03 リートー ラボラトリーズ カンパニー リミテッド Ｆｇｆ２１変異タンパク質及びその応用
US20250302919A1 (en) 2021-10-13 2025-10-02 Akero Therapeutics, Inc. Pharmaceutical compositions of efruxifermin
CN113980147B (zh) * 2021-11-26 2023-07-28 中国药科大学 一种聚多肽与fgf21融合蛋白突变体及其应用
WO2023173021A2 (fr) * 2022-03-11 2023-09-14 The Board Of Regents Of The University Of Texas System Méthodes et compositions de traitement de la toxicité d'alcool
AU2023343076A1 (en) 2022-09-12 2025-03-27 Akero Therapeutics, Inc. Fgf21 mutant polypeptides
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques
WO2024218715A1 (fr) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Milieu de culture à base d'hydrolysat de protéines et leur procédé de préparation
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2025155843A1 (fr) 2024-01-19 2025-07-24 Akero Therapeutics, Inc. Méthode de traitement d'une lésion hépatique ou pulmonaire
TW202547887A (zh) * 2024-05-31 2025-12-16 大陸商上海齊魯製藥研究中心有限公司 融合蛋白分子及其應用

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436366A (en) 1981-02-17 1984-03-13 E. I. Du Pont De Nemours And Company End capping an optical fiber
AR230173A1 (es) 1981-06-29 1984-03-01 American Cyanamid Co Instrumento para ligaciones quirurgicas
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3478642D1 (en) 1983-07-29 1989-07-13 Mitsubishi Electric Corp Solid state overcurrent detector
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
CA1310924C (fr) 1986-04-24 1992-12-01 Francis P. Mccormick Systeme d'administration d'un medicament a l'aide de particules infectieuses
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
WO1991000916A2 (fr) * 1989-07-06 1991-01-24 The Regents Of The University Of California Recepteurs pour facteurs de croissance de fibroblastes
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DE779362T1 (de) 1989-12-22 2001-04-05 Applied Research Systems Ars Holding N.V., Curacao DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (fr) 1990-01-08 1991-07-25 Brown University Research Foundation Dispositifs et procedes d'apport ameliore de facteurs actifs
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
ATE243253T1 (de) 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H Rezeptoren der wachstumsfaktoren aus fibroblasten
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DK0646182T3 (da) * 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA2162275A1 (fr) 1993-05-07 1994-11-24 Robert George Flynn Lait et produits laitiers a lactose hydrolyse, au gout ameliore et a sucrosite reduite
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
WO1994028122A1 (fr) 1993-05-26 1994-12-08 Ontario Cancer Institute Mammiferes transgeniques chez qui manque l'expression d'isoformes cd45 particuliers
EP0705334A1 (fr) 1993-06-14 1996-04-10 Basf Aktiengesellschaft Maitrise precise de l'expression des genes dans les cellules encaryotes au moyen de promoteurs reagissant a la tetracycline
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
JPH11506319A (ja) 1995-05-26 1999-06-08 ゼネカ・リミテッド エクジソンレセプターを含む遺伝子スイッチ
JPH11506722A (ja) 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
WO1997031898A1 (fr) 1996-02-28 1997-09-04 Ariad Gene Therapeutics, Inc. Derives synthetiques de rapamycine utilises comme agents de multimerisation de proteines chimeres a domaines derives de l'immunophiline
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
KR20000062345A (ko) * 1996-12-26 2000-10-25 히라타 다다시 신규 폴리펩타이드, 신규 ｄｎａ 및 신규 항체
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1032668B1 (fr) 1997-11-25 2008-05-28 Genentech, Inc. Facteur de croissance des fibroblastes 19
US6150098A (en) 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
NL1010174C1 (nl) 1998-09-24 2000-03-27 Busschers Metaalbedrijf Bv Inrichting en werkwijze voor het buigen van buisvormig en staafvormig materiaal.
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6369109B1 (en) 1998-10-28 2002-04-09 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor
WO2000027885A1 (fr) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
WO2000046380A2 (fr) 1999-02-08 2000-08-10 Chiron Corporation Fusion du recepteur du facteur de croissance des fibroblastes avec une immunoglobuline
CA2367375A1 (fr) 1999-03-15 2000-09-21 Chiron Corporation Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil
CA2311201A1 (fr) 1999-08-05 2001-02-05 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (fr) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US6254671B1 (en) 1999-11-15 2001-07-03 Engelhard Corporation Very green-shade yellow metallized disazo pigment
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
US7108984B2 (en) * 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
WO2001049849A1 (fr) 2000-01-05 2001-07-12 Zymogenetics, Inc. Zfgf11 : nouvel homologue de fgf
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20060223114A1 (en) * 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20040018499A1 (en) 2001-06-06 2004-01-29 Lal Preeti G Extracellular messengers
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
WO2003011213A2 (fr) 2001-07-30 2003-02-13 Eli Lilly And Company Methode de traitement du diabete et de l'obesite
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
WO2003059270A2 (fr) 2002-01-15 2003-07-24 Eli Lilly And Company Methode de diminution de la morbidite et de la mortalite chez des patients gravement malades
ES2363765T3 (es) * 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
EP1332761A1 (fr) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistes des récepteurs du facteur de croissance des fibroblastes
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP2003334088A (ja) 2002-05-22 2003-11-25 Pharma Design Inc ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
AU2003284357A1 (en) 2002-11-01 2004-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2510715A1 (fr) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Methode de modulation de l'interaction d'un recepteur et d'un ligand
TWI300430B (en) 2003-01-10 2008-09-01 Ritek Corp Optical recording medium dye and optical recording medium using thereof
WO2004083381A2 (fr) 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
ATE385806T1 (de) 2003-06-12 2008-03-15 Lilly Co Eli Fusionsproteine
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
WO2005019258A2 (fr) 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
JP4049723B2 (ja) 2003-09-04 2008-02-20 沖電気工業株式会社 窒化物半導体素子の製造方法及び窒化物半導体素子の製造装置
SI1680140T1 (sl) 2003-10-16 2011-08-31 Imclone Llc Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
EP2270163A1 (fr) * 2003-12-10 2011-01-05 Eli Lilly and Company Mutéines du facteur de croissance des fibroblastes
WO2005066211A2 (fr) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique
WO2005072769A1 (fr) 2004-01-26 2005-08-11 Eli Lilly And Company Utilisation du fgf-21 et d'une thiazolidinedione dans le traitement du diabete de type 2
WO2005091944A2 (fr) 2004-03-17 2005-10-06 Eli Lilly And Company Composes fgf-21 lies au glycol
JP4505631B2 (ja) 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
EP1789443A1 (fr) 2004-09-02 2007-05-30 Eli Lilly And Company Muteines du facteur de croissance 21 du fibroblaste
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP2474316B1 (fr) 2004-10-07 2016-04-06 The Regents of The University of California Analogues de toxine SHK et leurs utilisations pour l'inhibition sélective des canaux de potassium KV1.3
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
JP2008522617A (ja) * 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
EP1846019A2 (fr) 2005-01-21 2007-10-24 Eli Lilly And Company Methode de traitement de maladie cardio-vasculaire
US20060193299A1 (en) * 2005-02-25 2006-08-31 Cicso Technology, Inc., A California Corporation Location-based enhancements for wireless intrusion detection
JP2006246823A (ja) 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用
WO2006130527A2 (fr) 2005-05-31 2006-12-07 Novartis Ag Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
EP1995321A2 (fr) 2005-08-15 2008-11-26 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
US7395962B2 (en) 2005-10-28 2008-07-08 United Parcel Service Of America, Inc. Pick up notice and method of using same
WO2007055789A2 (fr) 2005-10-31 2007-05-18 Neose Technologies, Inc. Expression de proteines therapeutiques solubles
WO2007056789A1 (fr) 2005-11-16 2007-05-24 Dier Corporation As Trustee For The Reid Family Superannuation Trust Nouveaux ensembles de cadres sur écrans de sécurité
CA2644046A1 (fr) 2006-02-28 2007-09-07 Trustees Of Boston University Regulateurs metaboliques et leurs utilisations
WO2007110079A2 (fr) * 2006-03-29 2007-10-04 Enkam Pharmaceuticals A/S Administration ciblée de ligands du récepteur fgrf au cerveau
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
TW201446265A (zh) * 2007-04-02 2014-12-16 建南德克公司 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途
US8697369B2 (en) * 2007-04-06 2014-04-15 National Institute Of Advanced Industrial Science And Technology Method for screening a test substance for activating a receptor associated with FGF 21 activity
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
EP2152295B1 (fr) 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Protéine klotho et composés apparentés destinés au traitement du cancer
BRPI0812384A2 (pt) 2007-05-22 2014-12-02 Novartis Ag Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21
EP2165715B1 (fr) 2007-05-29 2013-12-18 Sapporo Medical University Agent thérapeutique contre le cancer et procédé de traitement du cancer
EP2162535A4 (fr) 2007-06-04 2011-02-23 Novo Nordisk As Glycosylation à liaisons o utilisant des n-acétylglucosaminyl transférases
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
GB2464062A (en) 2007-08-08 2010-04-07 Foster Miller Inc Watercraft drogue system
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009117622A2 (fr) 2008-03-19 2009-09-24 Ambrx, Inc. Polypeptides fgf-23 modifiés et leurs utilisations
SG193860A1 (en) * 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010006214A1 (fr) 2008-07-09 2010-01-14 Ambrx, Inc. Anticorps de neutralisation de fgf-21 et leurs utilisations
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
JP2012530493A (ja) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
CA2777717C (fr) 2009-10-15 2021-05-25 Genentech, Inc. Facteurs de croissance chimeriques des fibroblastes avec specificite de recepteur modifiee
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011130417A2 (fr) 2010-04-15 2011-10-20 Amgen Inc. Protéines de liaison au récepteur de fgf humain et à β-klotho
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP2548570A1 (fr) 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
WO2013033452A2 (fr) 2011-08-31 2013-03-07 Amgen Inc. Procédé de traitement ou d'amélioration du diabète type i employant fgf21
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.

Also Published As

Publication number Publication date
CN102143758A (zh) 2011-08-03
MX346396B (es) 2017-03-16
US20190023757A1 (en) 2019-01-24
BR122020010972B1 (pt) 2021-05-18
MX2010013333A (es) 2011-04-05
US20140243503A1 (en) 2014-08-28
US20120003216A1 (en) 2012-01-05
TWI403519B (zh) 2013-08-01
WO2009149171A4 (fr) 2010-05-06
KR101787300B1 (ko) 2017-10-18
US11072640B2 (en) 2021-07-27
MY152721A (en) 2014-11-28
US20090305986A1 (en) 2009-12-10
EA201690946A1 (ru) 2017-05-31
WO2009149171A3 (fr) 2010-03-11
JP2016128449A (ja) 2016-07-14
CO6341566A2 (es) 2011-11-21
NZ590050A (en) 2012-08-31
JP6810190B2 (ja) 2021-01-06
JP7191076B2 (ja) 2022-12-16
CL2010001346A1 (es) 2011-06-03
KR20110025810A (ko) 2011-03-11
CA2726589C (fr) 2017-06-13
AU2009256232A1 (en) 2009-12-10
EA201270758A1 (ru) 2013-12-30
TW201219052A (en) 2012-05-16
US8034770B2 (en) 2011-10-11
US11840558B2 (en) 2023-12-12
US20210317176A1 (en) 2021-10-14
US8361963B2 (en) 2013-01-29
IL209395A0 (en) 2011-01-31
US9273106B2 (en) 2016-03-01
JOP20190083B1 (ar) 2025-10-01
CA2726589A1 (fr) 2009-12-10
US20120087920A1 (en) 2012-04-12
CR11851A (es) 2011-05-13
US20240076333A1 (en) 2024-03-07
AR072009A1 (es) 2010-07-28
TWI526220B (zh) 2016-03-21
JP2021052780A (ja) 2021-04-08
US20160168223A1 (en) 2016-06-16
BRPI0911385B1 (pt) 2021-04-13
JP2011523561A (ja) 2011-08-18
US20120093815A1 (en) 2012-04-19
EA017690B1 (ru) 2013-02-28
MA33142B1 (fr) 2012-03-01
CN102143758B (zh) 2015-11-25
KR101651697B1 (ko) 2016-08-29
BRPI0911385A2 (pt) 2019-03-26
EP2296690B1 (fr) 2016-11-30
SG193860A1 (en) 2013-10-30
JP2018082699A (ja) 2018-05-31
TW201010715A (en) 2010-03-16
JOP20190083A1 (ar) 2017-06-16
IL209395A (en) 2014-08-31
US10011642B2 (en) 2018-07-03
AU2009256232B2 (en) 2011-12-22
JP6250714B2 (ja) 2017-12-20
EP2296690A2 (fr) 2011-03-23
KR20160046929A (ko) 2016-04-29
JP2019187417A (ja) 2019-10-31
US20250136653A1 (en) 2025-05-01
EA034847B1 (ru) 2020-03-27
US8410051B2 (en) 2013-04-02
PE20100253A1 (es) 2010-04-10
EA201001883A1 (ru) 2011-06-30
JP6960832B2 (ja) 2021-11-05
US8642546B2 (en) 2014-02-04
EA024751B8 (ru) 2020-01-31
WO2009149171A2 (fr) 2009-12-10
EA024751B1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
BRPI0911385A2 (pt) mutantes fgf21 e seus usos
UY38740A (es) Mutantes de fgf21 y usos del mismo
EA201990619A1 (ru) Fgf21 мутанты и их применение
WO2010129600A3 (fr) Mutants de fgf21 et leurs utilisations
MX2009002816A (es) Proteinas de fusion de albumina.
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
WO2007146038A3 (fr) Protéines de fusion d'albumine
ECSP088262A (es) Proteínas de fusión de albúmina
EA201892554A1 (ru) Мутант cd200 и его применения
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
UA102395C2 (en) Fgf21 mutants and use thereof
TN2011000553A1 (en) Fgf21 mutants and uses thereof
TN2010000563A1 (en) Fgf 21 mutants and uses thereof
TH96573B (th) Fgf21 มิวแทนท์ และการใช้ของสิ่งเหล่านี้

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2623 DE 13/04/2021 QUANTO AO PAIS DE ORIGEM.